Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) will release its fourth quarter and full year 2025 financial results and hold an earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The earnings release will be issued after market close the same day.
Management will provide a financial overview and business update; a live webcast and archived replay will be available at the company's Investor Relations website. Company executives will also appear at three investor healthcare conferences in March 2026.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
MYGN slipped 0.88% while close peers were mixed: FLGT +1.96%, CDNA +1.29%, CSTL +4.11%, PSNL -2.84%, NEO +0.53%. Momentum scanner only flagged PSNL, suggesting stock-specific trading rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | MRD launch update | Positive | +1.9% | Planned Precise MRD launch with strong ctDNA sensitivity data. |
| Jan 12 | Prelim results & guide | Positive | -0.1% | Preliminary 2025 revenue ranges and 2026 revenue/EBITDA guidance. |
| Jan 05 | Conference presentation | Neutral | +0.0% | J.P. Morgan Healthcare Conference presentation announcement and webcast details. |
| Dec 09 | SABCS abstracts | Positive | +4.0% | Eight SABCS abstracts on MRD, hereditary cancer, and risk testing. |
| Nov 25 | AI risk platform | Positive | -3.9% | Launch of integrated AI and genetic breast cancer risk platform. |
Recent news has mostly triggered modest, directionally aligned moves, with occasional divergences on guidance and partnership updates.
Over the past few months, Myriad reported multiple strategic and clinical developments. MRD commercialization and breast cancer study data on Jan 27, 2026 saw a +1.89% move. Preliminary 2025 results and 2026 guidance on Jan 12, 2026 coincided with a small -0.15% change. Scientific visibility, including eight SABCS abstracts on Dec 9, 2025, drove a +3.96% reaction, while an AI breast health platform announcement on Nov 25, 2025 saw a -3.92% move. Today’s earnings-date notice fits this cadence of frequent, incremental updates.
Market Pulse Summary
This announcement schedules Myriad’s fourth quarter and full year 2025 earnings call for February 23, 2026 at 4:30 pm ET and outlines participation in three healthcare investor conferences in early March. It adds to a steady cadence of recent updates on MRD commercialization, preliminary 2025 results, and clinical data. Investors may focus on the final audited figures versus January’s preliminary ranges and any changes to 2026 guidance or strategic priorities discussed on the call.
AI-generated analysis. Not financial advice.
Management will participate in three upcoming investor healthcare conferences
SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2025.
A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
Upcoming Investor Conferences
Sam Raha, President and CEO, and Ben Wheeler, Chief Financial Officer, will participate in the following investor healthcare conferences:
- The TD Cowen 46th Annual Health Care Conference in a fireside chat at 3:10 pm ET on Tuesday, March 3, 2026.
- The Leerink Partners Global Healthcare Conference in a fireside chat at 1:40 pm ET on Tuesday, March 10, 2026.
- The Barclays 28th Annual Global Healthcare conference in 1-on-1 meetings on Wednesday, March 11, 2026.
Live and archived webcasts of presentations at TD Cowen and Leerink Partners can be viewed at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(385) 318-3718
PR@myriad.com
FAQ
When will Myriad Genetics (MYGN) release Q4 and full year 2025 results and hold the earnings call?
How can investors access Myriad Genetics (MYGN) live earnings webcast on Feb. 23, 2026?
Can investors join Myriad Genetics (MYGN) earnings call by telephone and how do they register?
Which Myriad Genetics executives will speak at investor conferences in March 2026?
When and where will Myriad present at the TD Cowen healthcare conference in March 2026?
Will Myriad Genetics (MYGN) provide archived webcasts of the March 2026 investor presentations?
